Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Current treatments for patients with Alzheimer disease Osborn GG; Saunders AVJ Am Osteopath Assoc 2010[Sep]; 110 (9 Suppl 8): S16-26There is neither proven effective prevention for Alzheimer disease nor a cure for patients with this disorder. Nevertheless, a spectrum of biopsychosocial therapeutic measures is available for slowing progression of the illness and enhancing quality of life for patients. These measures include a range of educational, psychological, social, and behavioral interventions that remain fundamental to effective care. Also available are a number of pharmacologic treatments, including prescription medications approved by the US Food and Drug Administration for Alzheimer disease, "off-label" uses of medications to manage target symptoms, and controversial complementary therapies. Physicians must make the earliest possible diagnosis to use these treatments most effectively. Physicians' goals should be to educate patients and their caregivers, to plan long-term care options, to maximally manage concurrent illnesses, to slow and ameliorate the most disabling symptoms, and to preserve effective functioning for as long as possible. The authors review the various current treatments for patients with Alzheimer disease.|Aggression[MESH]|Alzheimer Disease/*drug therapy/psychology/therapy[MESH]|Behavior Therapy[MESH]|Cholinesterase Inhibitors/therapeutic use[MESH]|Depression/etiology[MESH]|Excitatory Amino Acid Antagonists/therapeutic use[MESH]|Galantamine/therapeutic use[MESH]|Health Status[MESH]|Humans[MESH]|Memantine/therapeutic use[MESH]|Neuroprotective Agents/therapeutic use[MESH]|Parasympathomimetics/therapeutic use[MESH]|Phenylcarbamates/therapeutic use[MESH]|Psychomotor Agitation/etiology[MESH]|Psychotherapy[MESH]|Psychotic Disorders/etiology[MESH]|Rivastigmine[MESH]|Time Factors[MESH]|United States[MESH]|United States Food and Drug Administration[MESH] |